Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | FABP4 | P15090 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL5874704 | 0.93 | HDAC3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Hexanoate SCHEMBL5875370 | 0.91 | AKR1B1 (0.76) | AKR1B1GPR84PPARGPPARDPPARA | |
| Butyric Acid SCHEMBL9351884 | 0.90 | HDAC3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8072838 | 0.90 | HDAC3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Heptanoate SCHEMBL5874166 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Nonanoate SCHEMBL5874969 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Stearic Acid SCHEMBL557515 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Dodecanoate SCHEMBL8469342 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Decanoic Acid SCHEMBL4910739 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Undecanoate SCHEMBL21145320 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015703-A2 | NOVEL 6-O-SUBSTITUTED 15-MEMBERED 8A- AND 9A-LACTAMS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2010-02-11 | — | — | WO | disclosed |
| US-7262172-B2 | Macrolides | GLAXO GROUP LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| EP-1328535-B1 | MACROLIDES | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20070066544-A1 | 3-Decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-03-22 | — | — | US | disclosed |
| US-20040254124-A1 | Macrolides | PLIVA D.D. (HR) | 2004-12-16 | — | — | US | disclosed |
| EP-1328535-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2003-07-23 | — | — | EP | disclosed |
| EP-1070077-B1 | 15-MEMBERED LACTAMS KETOLIDES WITH ANTIBACTERIAL ACTIVITY | PLIVA PHARM & CHEM WORKS (HR) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002032917-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
| EP-1070077-A1 | 15-MEMBERED LACTAMS KETOLIDES WITH ANTIBACTERIAL ACTIVITY | Pliva, Farmaceutska, Industrija, Dionicko Drustvo (HR) | 2001-01-24 | — | — | EP | disclosed |
| US-6110965-A | USEFUL FOR TREATING BACTERIAL INFECTIONS IN HUMANS AND ANIMALS | PLIVA, FARMACEUTSKA, KEMIJSKA, PREHRAMBENA I KOZMETICKA INDUSTRIJA, DIONICKO DRUSTVO (HR) | 2000-08-29 | — | — | US | disclosed |
| WO-1999051616-A1 | 15-MEMBERED LACTAMS KETOLIDES WITH ANTIBACTERIAL ACTIVITY | PLIVA, FARMACEUTSKA, INDUSTRIJA, DIONICKO DRUSTVO (HR) | 1999-10-14 | — | — | WO | disclosed |
| EP-0153803-A2 | Triazole antifungal agents | Pfizer Limited (GB) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254124-A1 | Macrolides | OGFOD1, TLR7, MALT1 | FFAR3 277/4885HDAC3 51/4885HDAC1 138/4885 |
| US-20070066544-A1 | 3-Decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a | DDOST, DHCR7, DAD1 | FFAR3 2950/4885HDAC3 424/4885HDAC1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.